Osmotic Demyelination Syndrome Resulting from an Unexpected Response to Tolvaptan in a Patient with Heart Failure.
- Author:
Kyehwan KIM
1
;
Min Gyu KANG
;
Jeong Rang PARK
;
Jin Yong HWANG
;
Choong Hwan KWAK
Author Information
- Publication Type:Case Report
- Keywords: Tolvaptan; Osmotic demyelination syndrome; Heart failure
- MeSH: Aged; Atrial Fibrillation; Demyelinating Diseases*; Female; Heart Failure*; Heart*; Humans; Hyponatremia; Prognosis; Receptors, Vasopressin
- From:Korean Journal of Medicine 2017;92(1):62-65
- CountryRepublic of Korea
- Language:Korean
- Abstract: Hyponatremia is commonly encountered in patients with heart failure and has a poor prognosis. Tolvaptan, a novel selective vasopressin V2 receptor blocker, has received attention as an effective drug for treating the syndrome of inappropriate antidiuretic hormone secretion and hypervolemic hyponatremia. However, the safety of tolvaptan in the treatment of hyponatremia is not clear. We experienced a 78-year-old woman with a history of heart failure, atrial fibrillation, and hyponatremia who developed osmotic demyelination syndrome as an unexpected response to treatment with tolvaptan.
